Table 4.
Subgroup analysis of changes in the updated Sydney system score over time in relation to duration of H2RA use.
| Sydney System Factor | H2RA Long-term Use (n = 16) | H2RA Short-term Use (n = 17) | p Value |
|---|---|---|---|
| Score Coefficient (Point), Per Year (95% CI) | |||
| Atrophy antrum | −0.037 (−0.117 to 0.044) | 0.045 (−0.056 to 0.147) | 0.382 |
| corpus | −0.034 (−0.067 to −0.001) | 0.005 (−0.056 to 0.066) | 0.108 |
| Metaplasia antrum | −0.053 (−0.100 to −0.0057) | −0.022 (−0.075 to 0.031) | 0.296 |
| corpus | −0.021 (−0.066 to 0.024) | −0.008 (−0.035 to 0.019) | 0.350 |
| Mononuclear cell antrum | −0.039 (−0.085 to 0.007) | −0.078 (−0.135 to −0.022) | 0.567 |
| corpus | −0.026 (−0.070 to 0.017) | −0.051 (−0.102 to −0.001) | 0.988 |
| Neutrophil antrum | −0.034 (−0.076 to 0.009) | −0.066 (−0.129 to −0.002) | 0.681 |
| corpus | −0.026 (−0.061 to 0.009) | −0.063 (−0.124 to −0.003) | 0.692 |
| H. pylori antrum | −0.023 (−0.057 to 0.010) | −0.065 (−0.144 to 0.015) | 0.443 |
| corpus | −0.035 (−0.084 to 0.014) | −0.038 (−0.091 to 0.015) | 0.633 |
Abbreviations: H2RA, histamine 2 receptor antagonist.